Overview

Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This study is to test the idea that a controlled release formulation of CE-224,535 may allow for less frequent dosing and exposure to lower levels of drug than an immediate release formulation.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer